β-arrestin-2 (ARRB2)

β-arrestin-2, encoded by the gene ARRB2, is a cytosolic adaptor protein recruited to agonist-activated, G-protein-receptor-kinase (GRK)-phosphorylated G-protein-coupled receptors (GPCRs). It performs three overlapping functions: desensitization (steric uncoupling of the receptor from heterotrimeric G proteins), clathrin-mediated internalization (trafficking the receptor into endosomes), and β-arrestin-biased signaling (scaffolding kinase cascades — ERK/MAPK, JNK3, Src, AKT — independently of G-protein activation). β-arrestin-2 is one of four mammalian arrestins (visual arrestin-1, cone arrestin, β-arrestin-1/ARRB1, and β-arrestin-2/ARRB2); it is the effector recruited by the atypical chemokine receptor ackr3 and mediates cxcr4 desensitization and internalization. Its documented roles in NF-κB suppression and cardiac aging make it peripherally relevant to hallmarks of aging, though it is not a canonical aging gene.

Identity

UniProt: P32121 (ARRB2_HUMAN) — Swiss-Prot, manually reviewed; 409 amino acids
Gene symbol: ARRB2 (HGNC-approved symbol since the 1990s; previous HGNC symbol ARR2; alias BARR2)
NCBI Gene ID: 409 (chromosome 17p13.2)
HGNC: 712
Ensembl: ENSG00000141480
Mouse ortholog: Arrb2 (NCBI Gene 216869; one-to-one ortholog; structure and GPCR-binding function are highly conserved)
GenAge: no entry — ARRB2 is not in the HAGR curated aging gene set as of 2026-06-15 gap/not-populated

Disambiguation from β-arrestin-1 (ARRB1): β-arrestin-1 (ARRB1, UniProt P49407, NCBI Gene 408, chromosome 11q13.2) is the closely related paralog. ARRB1 and ARRB2 share ~78% sequence identity and largely overlapping GPCR substrates, but differ in nuclear trafficking (ARRB1 translocates to the nucleus more readily), tissue expression distributions, and some receptor preferences. ACKR3 recruits β-arrestin-2 preferentially ¹; CXCR4 recruits both isoforms. Unless otherwise specified, claims on this page refer to ARRB2 only.

Protein architecture and post-translational modifications

β-arrestin-2 adopts a bi-lobed “clam shell” fold consisting of N-domain and C-domain β-sandwich structures joined by a polar core. Agonist-bound, GRK-phosphorylated GPCR cytoplasmic tails disrupt the polar core hydrogen bonds, triggering an activation conformational change that exposes surfaces for simultaneous interactions with the receptor C-tail, clathrin, adaptor protein 2 (AP2), and downstream signaling effectors ².

Key structural features:

Phospho-sensor region (N-domain): contacts GRK-phosphorylated serine/threonine residues on the receptor C-tail; defines receptor selectivity
Clathrin box motif: recruits clathrin heavy chain for endocytic vesicle formation
AP2-binding site: engages clathrin adaptor AP2 (α-adaptin subunit) for pit localization
C-tail: intrinsically disordered; contains sites phosphorylated by casein kinase II (CK2) and protein kinase A (PKA) that modulate arrestin’s own clathrin binding affinity ³
Finger loop: inserts into the GPCR transmembrane core upon high-affinity “tail + core” binding; stabilizes the active arrestin state

The protein’s multiple simultaneous binding surfaces explain its multifunctional scaffold role: a single β-arrestin-2 molecule can bridge an active GPCR, clathrin, AP2, and a kinase scaffold protein simultaneously.

Core mechanisms

1. GPCR desensitization

The canonical desensitization sequence is: GPCR agonist activation → GRK2/3/5/6 phosphorylation of receptor serine/threonine residues → β-arrestin-2 recruitment → steric occlusion of the G-protein-binding interface on the receptor → G-protein uncoupling. β-arrestin-2 binding therefore terminates the G-protein signal independently of receptor removal from the membrane. The best-characterized in vivo example is opioid receptor desensitization: β-arrestin-2 knockout mice showed dramatically potentiated and prolonged morphine analgesia, confirming that ARRB2 limits mu-opioid receptor (MOR) G-protein signaling in native tissue ⁴.

2. Clathrin-mediated receptor internalization

After desensitization, β-arrestin-2 simultaneously contacts clathrin and AP2, nucleating a clathrin-coated pit around the receptor-arrestin complex. The receptor is then internalized into endosomes. From endosomes, receptors are sorted: “class A” GPCRs (e.g., β2-adrenergic receptor, β2AR) dissociate from β-arrestin-2 in early endosomes and recycle rapidly to the plasma membrane (resensitization); “class B” GPCRs (e.g., angiotensin II type 1 receptor, AT1R; vasopressin V2 receptor) form stable “megaplex” structures that traffic together with β-arrestin-2 into recycling endosomes, enabling sustained β-arrestin-dependent signaling from intracellular compartments ². β-arrestin-2 is thus both the initiator of desensitization and the vehicle by which “desensitized” receptors continue to signal from endosomes via a G-protein-independent route.

3. β-arrestin-biased signaling (scaffolding)

Independently of G-protein signaling, β-arrestin-2 scaffolds several kinase complexes on internalized receptors:

MAPK cascade: β-arrestin-2 acts as a scaffold for ASK1–MKK4–JNK3 (c-Jun N-terminal kinase 3), bringing the entire kinase module under GPCR control ⁵. Endosomal β-arrestin-GPCR complexes also scaffold ERK1/2 activation, producing spatially distinct (cytoplasmic, endosomal) ERK activity compared to nuclear ERK from G-protein-dependent activation.
AKT/GSK3: β-arrestin-2 forms a signaling complex with Akt, protein phosphatase 2A (PP2A), and Gβγ downstream of dopamine D2 receptors, controlling glycogen synthase kinase 3 (GSK3) phosphorylation; this complex is disrupted by lithium, explaining part of lithium’s therapeutic mechanism ⁶.
Src/focal adhesion kinase: β-arrestin-2 recruits Src to the β2AR, activating ERK via a G-protein-independent route.

This “biased” output — distinct from classic G-protein signals — is therapeutically significant because it allows biased agonists that selectively activate either G-protein or β-arrestin pathways via the same receptor.

Relevance to the CXCL12/ACKR3/CXCR4 chemokine axis

β-arrestin-2 is the primary intracellular effector for ackr3 (atypical chemokine receptor 3). ACKR3 is a seven-transmembrane decoy receptor that lacks functional G-protein coupling; its sole confirmed canonical output is β-arrestin-2 recruitment ¹. In transiently transfected HEK293 cells, β-arrestin-2 recruitment to ACKR3 drives MAPK (pERK) activation. In native rat vascular smooth muscle cells expressing endogenous ACKR3, β-arrestin-2 siRNA knockdown significantly attenuated CXCL11 (ITAC)-stimulated cell migration (p<0.05; β-arrestin-1 knockdown had no effect) — establishing β-arrestin-2 as the functional transducer in at least some cell types with endogenous receptor expression ¹. This makes β-arrestin-2 the downstream signal relay for the ACKR3-dependent component of CXCL12 gradient shaping in the bone-marrow niche and vascular endothelium (see ackr3 and cxcl12).

For cxcr4, β-arrestin-2 (together with β-arrestin-1) mediates the canonical desensitization/internalization sequence following CXCL12 stimulation: GRK2/3 phosphorylate the CXCR4 C-terminal tail, β-arrestin is recruited, and the receptor is internalized. The WHIM syndrome C-terminal truncation mutations (documented on cxcr4) remove the GRK phosphorylation docking sites and thereby impair β-arrestin recruitment — explaining the pathological gain-of-function phenotype of prolonged, unquenched CXCR4 signaling.

β-arrestin-2 is therefore a shared downstream effector for both arms of the CXCL12 axis: the scavenging/biased arm (ACKR3) and the classical signaling arm’s desensitization (CXCR4). See cxcl12-cxcr4-pathway for the integrated pathway context.

Inflammation and NF-κB regulation

β-arrestin-2 negatively regulates innate inflammatory signaling, specifically the Toll-like receptor (TLR) / NF-κB (nuclear factor kappa B) axis:

TLR4/NF-κB suppression: β-arrestin-2 knockout mice showed markedly worse lipopolysaccharide (LPS)-induced liver injury with significantly elevated IL-1β, IL-6, and TNF-α versus wild-type controls; β-arrestin-2 siRNA knockdown in RAW264.7 macrophages increased phospho-IκBα and phospho-p65 NF-κB subunit ⁷. This establishes β-arrestin-2 as a brake on TLR4-driven innate inflammation.
Chondrocyte NF-κB: In mouse chondrocytes stimulated with pro-inflammatory 4-mer hyaluronan oligosaccharides, β-arrestin-2 blockade significantly potentiated the inflammatory response via release of p38 MAPK suppression and NF-κB de-repression ⁸.
GPR81/lactate inflammasome axis: Lactate-GPR81-β-arrestin-2 signaling negatively regulates TLR-driven NLRP3 inflammasome activation, reducing IL-1β production; β-arrestin-2 is required for GPR81’s anti-inflammatory metabolic signaling ⁹.

The mechanistic basis for NF-κB suppression is not fully elucidated but likely involves β-arrestin-2 sequestering IκBα from phosphorylation by IKK or scaffolding suppressive phosphatases. Importantly, β-arrestin-2’s anti-inflammatory role in innate immunity is not a GPCR desensitization effect but an independent scaffold function engaged by TLR/metabolic-receptor agonism. Whether age-related decline in β-arrestin-2 expression or activity contributes to inflammaging is not established. gap/needs-replication

Dimension	Status
NF-κB suppression mechanism conserved in humans?	partial — mouse KO data; human mechanistic evidence from in vitro knockdown
Phenotype replicated in aging?	no — inflammatory studies used young mice; aging-specific data absent
Replicated independently?	yes — multiple independent in vitro/in vivo systems confirm ARRB2 as NF-κB brake

Cardiac aging relevance

The most directly aging-specific evidence for β-arrestin-2 comes from cardiac biology. β-arrestin-2 desensitizes β-adrenergic receptors (β1AR, β2AR) — the dominant GPCR system governing cardiac contractility. Chronic catecholamine stimulation in heart failure drives maladaptive β-AR signaling partly through GRK2 upregulation and excessive desensitization; β-arrestin-2 participates in this process and also scaffolds protective AKT and anti-apoptotic signals from endosomal β-ARs.

Aging-specific evidence (mouse): β-arrestin-2 knockout mice at 12–16 months of age (vs. 3–6 month young controls) showed KO-specific depressed contractility parameters — prolonged aortic ejection time and decreased velocity of circumferential fiber shortening — with preserved ejection fraction (≥50% in all groups), plus KO-specific impaired diastolic relaxation (slower e′ velocity, higher E/e′ ratio, prolonged isovolumetric relaxation time) ¹⁰. Notably, left atrial and left ventricular internal diameter enlargement occurred in both aged WT and aged KO mice (a normal aging effect), and was not KO-specific. Myofilament protein phosphorylation patterns were altered in aged KO mice (increased cMyBP-C phosphorylation at Ser302, decreased RLC phosphorylation). These contractility and diastolic dysfunction deficits were absent in young KO mice, indicating that β-arrestin-2 signaling specifically becomes protective during cardiac aging rather than development. Statistical analysis used two-way ANOVA with Fisher’s LSD post-hoc testing (p<0.05; n=5–13 per echocardiography group).

Diabetes/cardiac intersection: Hyperinsulinemia activates β2AR in a β-arrestin-2-dependent manner (via GRK2 transactivation), contributing to diabetes-associated cardiac dysfunction; β-arrestin-2 knockout mice on high-fat diet were protected from this specific insulin-mediated β2AR transactivation pathway ¹¹.

Dimension	Status
Pathway conserved in humans?	yes — β-arrestin-2 / β-AR / GRK2 axis is the same in human heart
Phenotype conserved in humans?	partial — diastolic dysfunction with aging is a major human phenotype; ARRB2-specific contribution not tested in humans
Replicated in humans?	no — genetic evidence absent; no human cardiac ARRB2 aging study gap/needs-human-replication

Biased agonism: drug-design implications

β-arrestin-biased agonism — ligands that activate β-arrestin pathways selectively without coupling to G proteins — is a major paradigm in drug development. For GPCRs where G-protein signaling mediates side effects and β-arrestin signaling mediates therapeutic benefit (or vice versa), biased agonists allow pathway selectivity ¹². Examples relevant to aging contexts:

Opioid pain/constipation trade-off: G-protein signaling from MOR mediates analgesia; β-arrestin-2 recruitment was historically thought to drive respiratory depression and constipation. TRV130 (oliceridine), a G-protein-biased MOR agonist, was designed to avoid β-arrestin recruitment and received FDA approval in 2020 for acute pain — the first approved biased GPCR agonist. Caveat: subsequent Arrb2-KO mouse studies have complicated this model by showing β-arrestin-2 is not the sole driver of opioid side effects ¹².
PTH1R bone formation: β-arrestin-biased PTH analogs drive anabolic bone formation without hypercalcemia, demonstrating that signaling selectivity can be therapeutically exploited at a receptor relevant to osteoporosis.
ACKR3: the entire biology of ACKR3 as a scavenging receptor is predicated on its constitutive β-arrestin-biased nature — it is pharmacologically interesting precisely because it proves that β-arrestin-2 recruitment alone (without G-protein coupling) constitutes a functional signaling program.

As the field has matured, it has become clear that β-arrestin “conformation” (determined by the specific phosphorylation pattern — the “barcode” — on the receptor C-tail) determines which downstream scaffold interactions are adopted, making arrestins more like “allosteric microprocessors” than simple on/off switches ¹³. This conformational diversity is not yet pharmacologically exploitable in an aging context.

Pharmacology and aging-context druggability

Aging-context druggability: null. β-arrestin-2 itself is an intracellular scaffold; it has no catalytic active site and no documented allosteric binding pocket amenable to small-molecule targeting. No clinical drug directly binds β-arrestin-2. The protein is instead indirectly modulated by:

Biased GPCR ligands at upstream receptors (e.g., oliceridine at MOR; biased β-AR ligands) — these are designed to favor or disfavor β-arrestin-2 recruitment at the receptor level; the arrestin itself is not the drug target.
GRK inhibitors (e.g., paroxetine as GRK2 inhibitor in heart failure research) — reduce receptor phosphorylation and therefore reduce β-arrestin-2 recruitment; GRK2 not β-arrestin-2 is the target.
Indirect modulation via receptor expression — anything that changes surface GPCR levels changes β-arrestin-2 engagement.

There is no ongoing clinical program targeting ARRB2 directly for any aging indication. The field’s drug-development focus is on the upstream GPCR, not on arrestin. Druggability tier is therefore null (no clinically tractable approach exists targeting ARRB2 directly for aging).

mr-causal-evidence: not-tested — No Mendelian randomization study has used ARRB2 expression quantitative trait loci (eQTLs) to test causal effects on aging-relevant outcomes. ARRB2 eQTLs exist in GTEx (chromosome 17p13.2); this is technically feasible. gap/needs-replication

Pathway membership

g-protein-coupled-receptor-signaling — central effector of GPCR desensitization and internalization across the entire GPCR superfamily
mapk-pathway — scaffolds ERK1/2 and JNK3 via β-arrestin-2-dependent endosomal signaling complexes
chemokine-signaling — sole confirmed effector for ACKR3; desensitization effector for CXCR4
cxcl12-cxcr4-pathway (stub) — participates through both ACKR3 (biased arm) and CXCR4 (desensitization arm)

Key interactors

ackr3 — ACKR3’s sole canonical intracellular signal transducer; β-arrestin-2 recruitment is the complete intracellular output of this scavenging decoy receptor
cxcr4 — β-arrestin-2 mediates CXCR4 desensitization and internalization after CXCL12 stimulation; WHIM mutations impair this step
CXCL12 — indirect interaction: CXCL12 activates CXCR4 and triggers β-arrestin-2 recruitment; also the ligand for ACKR3 that drives β-arrestin-2 scavenging internalization

Limitations and gaps

No aging-specific expression data. Whether ARRB2 expression or recruitment efficiency changes with aging in immune cells, cardiomyocytes, or stem-cell niches has not been characterized systematically. Reduced ARRB2 in aged macrophages could compound inflammaging; in cardiomyocytes it would worsen diastolic dysfunction. gap/needs-replication
Cardiac aging mechanism incomplete. The Capote 2021 study establishes that β-arrestin-2 is protective in aged hearts but does not identify the specific GPCR substrate(s) involved — whether it is β-AR desensitization, endosomal AKT signaling, or another receptor system. gap/no-mechanism
NF-κB suppression molecular mechanism unresolved. How β-arrestin-2 attenuates IκBα phosphorylation or p65 nuclear translocation at a biochemical level is not established. Whether it directly binds IKK, competes with IκBα, or recruits phosphatases is unclear. gap/no-mechanism
GTEx aging correlation unpopulated. Tissue-by-age ARRB2 expression trajectories have not been extracted for this page. Populate per sops/finding-tissue-expression.md. gap/not-populated
MR causal evidence absent. No MR study has tested ARRB2 expression as a causal determinant of any aging outcome. gap/needs-replication
Biased-agonism controversy ongoing. The clean β-arrestin-signaling / G-protein-signaling dichotomy has been complicated by “megaplex” structures (simultaneous G-protein + β-arrestin engagement), revised KO phenotypes, and conformational-barcode complexity. Claims about “β-arrestin-only” outputs should be interpreted cautiously. gap/contradictory-evidence

Footnotes

doi:10.1073/pnas.0912852107 · PMID 20018651 · Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ · Proc Natl Acad Sci USA 2010;107(2):628–632 · in-vitro + in-vivo (rat VSMCs) · foundational demonstration that CXCR7/ACKR3 is β-arrestin-biased; β-arrestin-2 siRNA significantly attenuated ITAC/CXCL11-stimulated migration in native VSMCs (p<0.05; β-arrestin-1 siRNA had no effect); MAPK activation was NOT detected in native VSMCs — only in HEK293 overexpression context; establishes β-arrestin-2 as ACKR3’s sole functional effector in cells with endogenous expression ↩ ↩² ↩³
doi:10.1042/BJ20031076 · PMID 12959637 · Shenoy SK, Lefkowitz RJ · Biochem J 2003;375(Pt 3):503–515 · review · comprehensive mechanistic review of β-arrestin multifunctionality as endocytic adapter (clathrin + AP2 binding), signaling scaffold (MAPK, Src), and receptor-trafficking regulator; establishes the “class A vs class B GPCR” dichotomy (transient vs stable arrestin binding) that determines receptor recycling fate ↩ ↩²
doi:10.1021/bi025705n · PMID 12186555 · Lin F-T, Chen W, Shenoy S, Bhatt M, Bhatt S, Lefkowitz RJ · Biochemistry 2002;41(34):10692–10699 · in-vitro (HEK293 transfection) · phosphorylation of β-arrestin-2 at CK2 sites regulates its association with clathrin, thereby modulating clathrin-mediated receptor internalization capacity; demonstrates that β-arrestin-2 activity is itself regulated by post-translational modification ↩
doi:10.1126/science.286.5449.2495 · PMID 10617462 · Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT · Science 1999;286(5449):2495–2498 · in-vivo (β-arrestin-2 knockout mice, C57BL/6) · foundational demonstration that β-arrestin-2 mediates desensitization of the mu-opioid receptor (MOR) in vivo; ARRB2 KO mice showed “remarkable potentiation and prolongation” of morphine analgesia; establishes that endogenous β-arrestin-2 limits GPCR G-protein signaling duration in native tissue ↩
doi:10.1126/science.290.5496.1574 · PMID 11090355 · McDonald PH, Chow CW, Miller WE, Laporte SA, et al. · Science 2000;290(5496):1574–1577 · in-vitro (HEK293 + in-vivo mouse hippocampus) · ~700 citations · foundational β-arrestin-2 scaffold paper; demonstrates that β-arrestin-2 acts as “a scaffold protein, which brings the spatial distribution and activity of this MAPK module under the control of a GPCR”; specifically shown for ASK1–MKK4–JNK3 complex; establishes independent signaling function beyond desensitization ↩
doi:10.1016/j.cell.2007.11.041 · PMID 18191226 · Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG · Cell 2008;132(1):125–136 · in-vivo (mouse, dopamine D2 receptor) + in-vitro · β-arrestin-2 forms a signaling complex with Akt, PP2A, and Gβγ downstream of D2R; lithium disrupts this complex to modulate Akt/GSK3 signaling and lithium-associated behavioral effects; demonstrates that β-arrestin-2 scaffolds therapeutically relevant AKT signaling independently of G-protein pathways ↩
doi:10.3748/wjg.v24.i2.216 · PMID 29375207 · Jiang MP, Xu C, Guo YW, Luo QJ, Li L, Liu HL, Jiang J, Chen HX, Wei XQ · World J Gastroenterol 2018;24(2):216–225 · in-vivo (β-arrestin-2 KO mice) + in-vitro (RAW264.7 macrophages, siRNA) · β-arrestin-2 KO mice showed significantly more severe LPS-induced liver injury and higher IL-1β, IL-6, TNF-α; β-arrestin-2 siRNA increased phospho-IκBα and phospho-p65 in macrophages; establishes ARRB2 as a direct brake on TLR4/NF-κB innate inflammatory signaling ↩
doi:10.1007/s11010-014-2246-5 · PMID 25318610 · Campo GM, Avenoso A, D’Ascola A, Scuruchi M, Calatroni A, Campo S · Mol Cell Biochem 2015;399(1-2):201–208 · in-vitro (mouse chondrocytes) · β-arrestin-2 blockade significantly potentiated inflammatory response to pro-inflammatory 4-mer hyaluronan oligosaccharides; mechanism involves p38 MAPK disinhibition and NF-κB de-repression; also cAMP/PKA pathway engagement; demonstrates ARRB2 as anti-inflammatory in musculoskeletal tissue context ↩
doi:10.1053/j.gastro.2014.03.014 · PMID 24657625 · Hoque R, Farooq A, Ghani A, Gorelick F, Mehal WZ · Gastroenterology 2014;146(7):1763–1774 · in-vitro + in-vivo (mouse) · lactate-GPR81-β-arrestin-2 axis negatively regulates NLRP3 inflammasome activation and reduces IL-1β; β-arrestin-2 required for GPR81’s anti-inflammatory effect at TLR signaling level; mechanistic link between metabolic sensing (lactate) and innate immune suppression via ARRB2 ↩
doi:10.3389/fphys.2021.696852 · PMID 34512376 · PMC8430342 · Capote AE, Batra A, Warren CM, Chowdhury SAK, Wolska BM, Solaro RJ, Rosas PC · Front Physiol 2021;12:696852 · in-vivo (β-arrestin-2 KO mice, 12–16 months vs 3–6 months; two-way ANOVA with Fisher’s LSD, p<0.05; n=5–13/group for echocardiography) · aged β-arrestin-2 KO mice showed KO-specific depressed systolic contractility (prolonged aortic ejection time, decreased circumferential fiber shortening velocity) with preserved EF ≥50%, and KO-specific impaired diastolic relaxation (slower e′, higher E/e′, prolonged IVRT); LA and LV diameter enlargement occurred in both aged WT and KO (normal aging effect, not KO-specific); altered myofilament phosphorylation in aged KO; phenotype absent in young KO — establishes ARRB2 signaling as specifically protective during cardiac aging; gold OA ↩
doi:10.1161/CIRCULATIONAHA.116.022281 · PMID 27815373 · Wang Q, Liu Y, Fu Q, Xu B, Zhang Y, Kim S, Tan R, Barbagallo F, West T, Anderson E, Wei W, Abel ED, Xiang YK · Circulation 2017;135(1):73–88 · in-vivo (high-fat diet mouse models; WT, β2AR KO, β-arrestin-2 KO) · hyperinsulinemia promotes cardiac dysfunction via insulin receptor → GRK2 → β-arrestin-2-dependent transactivation of β2AR and elevation of PDE4D; β-arrestin-2 KO mice on HFD protected from insulin-mediated β2AR transactivation cardiac phenotype; intersects diabetes-related cardiac aging with ARRB2 biology ↩
doi:10.1016/j.molmed.2010.11.004 · PMID 21183406 · Whalen EJ, Rajagopal S, Lefkowitz RJ · Trends Mol Med 2011;17(3):126–139 · review · Lefkowitz group landmark review of biased agonism and β-arrestin-biased signaling; frames β-arrestins as “multifunctional adapters that promote distinct intracellular signals in their own right”; introduces therapeutic framework for G-protein-biased vs β-arrestin-biased drug design; covers opioid analgesia, cardiac, and other receptor systems; notes complexity of the opioid biased-agonist model ↩ ↩²
doi:10.1038/nrd.2017.229 · PMID 29302067 · Smith JS, Lefkowitz RJ, Bhattacharya S · Nat Rev Drug Discov 2018;17(4):243–260 · review · proposes that GPCRs function as “multistate allosteric microprocessors” where “biased ligands transmit distinct structural information” selectively activating G proteins or β-arrestins; frames the field as more conformationally complex than simple biased-switch models; key reference for nuanced understanding of β-arrestin pathway selectivity ↩

🧬 Aging Wiki

Explorer

beta-arrestin2